Navigate to
-
This decision to remove REMS comes one year after the FDA loosened REMS requirements and removed the site mandate for CAR T educational and training materials because they deemed the product label...
-
Scientists have made remarkable progress in understanding the thousands of genes inside our cells and the link they may have to cancer. Researchers continue to discover patient-specific...
-
Successfully complete new hire orientation Complete training to gain competency in SA, RxClaims and MSA Toolbox Attend Prime intern activities, such as volunteer opportunities and intern lunch and...
-
Therapy options Keytruda (Pembrolizumab) Adstiladrin (nadofaragene firadenovec-vncg) Anktiva (nogapendekin alfa inbakicept-pmln) + BCG Study KEYNOTE-057, phase 2, open label; 5-year follow-up;...
-
References National Cancer Institute. (2020, October 26). Radiopharmaceuticals: radiation therapy enters the molecular age....
-
Medication insights: teprotumumab-trbw (Tepezza) The U.S. Food and Drug Administration (FDA) first approved teprotumumab-trbw (Tepezza) in January 2020 for the treatment of thyroid eye disease...
-
Effective: January 2021 Terms of use IF YOU ARE EXPERIENCING A MEDICAL EMERGENCY, DIAL 911 AND/OR SEEK IMMEDIATE ATTENTION FROM A HEALTH CARE PROVIDER. THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE....
-
-
Forbes
PA Sub-Categories: GLP-1 Prime Article: In the News -
Cover image for Prime Therapeutics prioritizes patient-centered care, stays ahead of oncology trends Prime simplifies the cancer care pathway through innovative solutions that help manage complex...
PA Sub-Categories: Products Specialty drugs Prime Article: Stories